Which companies overlap with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.'s portfolio?

Top competitors by shared drug class: Pfizer, Astellas Pharma Inc, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/hangzhou-zhongmei-huadong-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. pipeline: 3 marketed, 0 filed, 13 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 13 Phase 3 2 Phase 2 11 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Wegovy ®	Wegovy ®	marketed
Ozempic®	Ozempic®	marketed	GLP-1 receptor agonist	GLP-1R (glucagon-like peptide-1 receptor)	Diabetes
ganagliflozin	ganagliflozin	marketed			Other
CAL/BDP Gel	CAL/BDP Gel	phase 3	Topical corticosteroid + vitamin D analogue combination	Vitamin D receptor (VDR), glucocorticoid receptor (GR)	Dermatology
HDM1002 placebo, oral, once daily, 52 weeks	HDM1002 placebo, oral, once daily, 52 weeks	phase 3
HDM1002 400mg, oral, once daily, 52 weeks	HDM1002 400mg, oral, once daily, 52 weeks	phase 3
HDM1002 200mg, oral, once daily, 52 weeks	HDM1002 200mg, oral, once daily, 52 weeks	phase 3
MB-102 OMID	MB-102 OMID	phase 3	CD47 inhibitor	CD47	Oncology
HDM1005 2	HDM1005 2	phase 3
MB-102 DMID	MB-102 DMID	phase 3	monoclonal antibody	CD47	Oncology
MC2-01 cream	MC2-01 cream	phase 3	Topical corticosteroid	Glucocorticoid receptor	Dermatology
HDM1702	HDM1702	phase 3			Oncology

Therapeutic area mix

Oncology · 3
Dermatology · 2
Diabetes · 1
Other · 1
Respiratory · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pfizer · 3 shared drug classes
Astellas Pharma Inc · 2 shared drug classes
AstraZeneca · 2 shared drug classes
Eli Lilly and Company · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
University of Pennsylvania · 2 shared drug classes
All India Institute of Medical Sciences, Bhubaneswar · 1 shared drug class
Al-Azhar University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hangzhou-zhongmei-huadong-pharmaceutical-co-ltd. Accessed 2026-05-17.